A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

The independent company will trade as Cortigent and advance brain implants to help people recover body functions such as ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing ...

Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...

The company wants to create two focused companies dedicated to driving current and future value in their respective ...

The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...

Our mission at Vivani remains unchanged as we continue to leverage our proprietary NanoPortal™ implant technology and advance the development of our portfolio of miniature, subdermal GLP-1 ...

Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results ...

Also Read: EXCLUSIVE: Vivani Medical Initiates First Human Clinical Trial With GLP-1 Implant For Weight Loss In Australia Vivani believes it is in the best interest of shareholders to spin off ...